Vectibix

Vectibix

panitumumab

Manufacturer:

Amgen

Distributor:

Zuellig
Concise Prescribing Info
Contents
Panitumumab
Indications/Uses
Treatment of adults w/ wild-type RAS metastatic colorectal cancer (mCRC) in 1st line in combination w/ FOLFOX or FOLFIRI; 2nd-line in combination w/ FOLFIRI for patients who have received 1st-line fluoropyrimidine-based chemotherapy (excluding irinotecan); as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, & irinotecan-containing chemotherapy regimens.
Dosage/Direction for Use
IV infusion 6 mg/kg once every 2 wk.
Contraindications
Hypersensitivity. Interstitial pneumonitis or pulmonary fibrosis. Combination w/ oxaliplatin-containing chemotherapy in patients w/ mutant RAS mCRC or for whom RAS mCRC status is unknown.
Special Precautions
Dermatologic reactions & soft tissue toxicity. Pulmonary complications. Permanently discontinue if ILD is diagnosed. Monitor for hypomagnesaemia & accompanying hypocalcaemia prior to initiating treatment, & periodically thereafter for up to 8 wk after the completion of treatment. Electrolyte disturbances. Infusion-related reactions. Acute renal failure. Discontinue treatment if ulcerative keratitis is confirmed. Patients w/ history of keratitis, ulcerative keratitis or severe dry eye. Patients w/ ECOG 2 performance status in combination w/ chemotherapy. May impair ability to drive or operate machinery. Pregnancy. Do not breastfeed during treatment & for 2 mth after the last dose. Childn. Elderly.
Adverse Reactions
Conjunctivitis, paronychia; anaemia; hypokalaemia, hypomagnesaemia, decreased appetite; insomnia; dyspnoea, cough; diarrhoea, nausea, vomiting, abdominal pain, stomatitis, constipation; dermatitis acneiform, rash, erythema, pruritus, dry skin, skin fissures, acne, alopecia; back pain; fatigue, pyrexia, asthenia, mucosal inflammation, peripheral oedema; decreased wt. Rash pustular, cellulitis, UTI, folliculitis, localised infection; leucopenia; hypersensitivity; hypocalcaemia, dehydration, hyperglycaemia, hypophosphataemia; anxiety; headache, dizziness; blepharitis, growth of eyelashes, increased lacrimation, ocular hyperaemia, dry eye, eye pruritus/irritation, tachycardia; DVT, hypotension, HTN, flushing; pulmonary embolism, epistaxis; rectal haemorrhage, dry mouth, dyspepsia, aphthous ulcer, cheilitis, GERD; skin ulcer, skin exfoliation, exfoliative rash, dermatitis, rash papular, rash pruritic, rash erythematous, rash generalised, rash macular, rash maculo-papular, skin lesion, skin toxicity, scab, hypertrichosis, onycholysis, nail disorder, hyperhidrosis, palmar-plantar erythrodysaesthesia syndrome; pain in extremity; chest pain, pain, chills; decreased blood Mg.
Drug Interactions
Avoid combination w/ irinotecan, bolus 5-fluorouracil & leucovorin (IFL) chemotherapy or bevacizumab-containing chemotherapy. Contraindicated w/ oxaliplatin-containing chemotherapy in patients w/ mutant RAS mCRC or for whom RAS mCRC status is unknown.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FE02 - panitumumab ; Belongs to the class of EGFR (Epidermal Growth Factor Receptor) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Vectibix infusion conc 20 mg/mL
Packing/Price
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in